131 related articles for article (PubMed ID: 4439501)
21. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
Pullmann H; Muth M
Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583
[No Abstract] [Full Text] [Related]
22. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection.
McKhann CF; Hendrickson CG; Spitler LE; Gunnarsson A; Banerjee D; Nelson WR
Cancer; 1975 Feb; 35(2):514-20. PubMed ID: 234291
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant therapy of cutaneous malignant melanoma: a critical review.
Koh HK; Sober AJ; Harmon DC; Lew RA; Carey RW
Med Pediatr Oncol; 1985; 13(5):244-60. PubMed ID: 3897817
[TBL] [Abstract][Full Text] [Related]
24. [Local immunotherapy. Alternative therapy for malignant cutaneous lesions (demonstration on 30 patients with malignant melanoma) (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1979 Mar; 91(5):150-4. PubMed ID: 425533
[TBL] [Abstract][Full Text] [Related]
25. Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the future.
Gutterman JU; Mavligit G; Reed R; Richman S; McBride CE; Hersh EM
Semin Oncol; 1975 Jun; 2(2):155-74. PubMed ID: 790574
[No Abstract] [Full Text] [Related]
26. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
[TBL] [Abstract][Full Text] [Related]
27. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
[TBL] [Abstract][Full Text] [Related]
28. The use of oral BCG in the treatment or metastatic malignant melanoma.
Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
[TBL] [Abstract][Full Text] [Related]
29. Results of administering B.C.G. to patients with melanoma.
Grant RM; Mackie R; Cochran AJ; Murray EL; Hoyle D; Ross C
Lancet; 1974 Nov; 2(7889):1096-100. PubMed ID: 4139404
[No Abstract] [Full Text] [Related]
30. Immune response and non-specific immunotherapy in melanoma.
El-Domeiri AA
Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
[TBL] [Abstract][Full Text] [Related]
31. Intralesional BCG in the treatment of metastatic malignant melanoma.
Mastrangelo MJ; Sulit HL; Prehn LM; Bornstein RS; Yarbro JW; Prehn RT
Cancer; 1976 Feb; 37(2):684-92. PubMed ID: 766947
[TBL] [Abstract][Full Text] [Related]
32. BCG in the treatment of human cancer.
Terry WD
CA Cancer J Clin; 1975; 25(4):198-203. PubMed ID: 805639
[No Abstract] [Full Text] [Related]
33. [Intrafocal BCG therapy of metastasizing malignant melanoma].
Kunze J; Lesch R; Plagwitz R; Hagedorn M
Hautarzt; 1978 Nov; 29(11):597-600. PubMed ID: 721465
[TBL] [Abstract][Full Text] [Related]
34. Treatment of malignant melanoma by intratumoral injection of BCG.
Pinsky CM; Hirshaut Y; Oettgen HF
Natl Cancer Inst Monogr; 1973 Dec; 39():225-8. PubMed ID: 4595322
[No Abstract] [Full Text] [Related]
35. Spontaneous regression of malignant melanoma.
Manelis G; Shasha SM; Manelis J; Suprun H; Robinson E
Oncology; 1978; 35(2):83-6. PubMed ID: 652267
[TBL] [Abstract][Full Text] [Related]
36. [Immunological aspects of melanoma].
Sjögren H
Lakartidningen; 1976 Feb; 73(7):528-30. PubMed ID: 1250045
[No Abstract] [Full Text] [Related]
37. [Unspecific immunological investigations in patients with malignant melanoma (author's transl)].
Knopf B; Wätzig V
Dermatol Monatsschr; 1982 Jan; 168(1):24-33. PubMed ID: 7044849
[No Abstract] [Full Text] [Related]
38. [Malignant melanoma. Clinicopathological analysis of 37 cases (author's transl)].
Hwang WS; Ding YA; Lee WC; Leu FJ
Taiwan Yi Xue Hui Za Zhi; 1982 Feb; 81(2):240-5. PubMed ID: 6954248
[No Abstract] [Full Text] [Related]
39. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
Kokoschka EM; Cerni C; Micksche M
Oncology; 1977; 34(5):229-33. PubMed ID: 917456
[TBL] [Abstract][Full Text] [Related]
40. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
